This week, 3 Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Vital Therapies, Inc. (VTL) gets a higher grade this week, advancing from a C last week to a B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of VTL stock.

This week, Cleveland BioLabs, Inc.’s (CBLI) ratings are up from a C last week to a B. Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries around programmed cell death to develop treatments for cancer and protection of normal tissues from radiation and other stresses. For more information, get Portfolio Grader’s complete analysis of CBLI stock.

Biocept, Inc. (BIOC) is seeing ratings go up from a C last week to a B this week. Biocept, Inc. is a global provider of clinical trials services, providing medical image management and eClinical services, including electronic data capture and clinical data management solutions. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of BIOC stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.